Showing 3121-3130 of 10618 results for "".
The Challenging Demands Faced by the Neurosurgeon
https://reachmd.com/programs/clinicians-roundtable/the-challenging-demands-faced-by-the-neurosurgeon/1120/Dr. Katrina Firlik, author of "Another Day in the Frontal Lobe: a Brain Surgeon Exposes Life on the Inside" discusses the practice of neurosurgery.Addressing Gaps in COPD Management: Insights for Pulmonary and Primary Care
https://reachmd.com/programs/deep-breaths-updates-chest/addressing-gaps-in-copd-management-insights-for-pulmonary-and-primary-care/33074/Patients with chronic obstructive pulmonary disease (COPD) often experience significant delays in diagnosis and treatment due to systemic gaps in management. A recent survey of 400 primary care and pulmonary clinicians uncovered patterns of fragmented care among both specialties. Join Dr. Nate FalkProblems During Emergency Situations
https://reachmd.com/programs/clinicians-roundtable/problems-during-emergency-situations/1053/What if you need to help someone who is a lawyer? What if your patient in the emergency department has a gun? Doctor Ronald Goodspeed, President and CEO of the Southcoast Hospitals Group in Massuchusetts discusses the answers in his recent book, "What If? A Survival Guide for Physicians."Sexuality After Cancer
https://reachmd.com/programs/clinicians-roundtable/sexuality-after-cancer/756/Join Dr. Kydd as she discusses intimacy and sexuality after surviving cancer.Supporting Adherence in Schizophrenia: The Role of Digital and Team-Based Tools
https://reachmd.com/programs/neurofrontiers/supporting-adherence-in-schizophrenia-with-digital-tools-and-teams/36645/Non-adherence to antipsychotic medication remains a major challenge in schizophrenia care, but multifaceted solutions are emerging. Joining Dr. Charles Turck to discuss how nurse-led education, digital tools like chatbots, and peer-to-peer support can work in tandem to overcome common adherence barrATTRibute-CM Findings on Acoramidis and Cumulative CV Events
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attribute-cm-acoramidis-cv-events/49036/An exploratory analysis of the ATTRibute-CM trial revealed that acoramidis meaningfully reduces cumulative cardiovascular events as early as one month into treatment. Learn more about these findings and their implications for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) as Ryan QuiglRedefining First-Line Therapy in mCSPC: Applying Evidence in Practice
https://reachmd.com/programs/project-oncology/redefining-first-line-therapy-in-mcspc-applying-evidence-in-practice/49229/Treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved significantly, moving beyond androgen deprivation therapy alone to more proactive combination approaches that can improve survival. Findings from key trials like CHAARTED, LATITUDE, and ARASENS have helped shape this sAssessing the Role of Metabolic Factors in Psoriasis Management
https://reachmd.com/programs/Audioabstracts/metabolic-factors-psoriasis-management/39678/Emerging research highlights a stronger-than-expected connection between body composition and psoriasis outcome, with a large real-world study examining how body mass index, basal metabolic rate, body surface area, and body weight impact both disease severity and biologic treatment response. Tune inOCT Biomarkers as Predictors of Treatment Response in RVO-Related Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/oct-biomarkers-as-predictors-of-treatment-response-in-rvo-related-macular-edema/37664/Retinal vein occlusion (RVO) is a leading cause of sudden vision loss, often complicated by macular edema that affects patient outcomes. While treatment options like anti-vascular endothelial growth factor agents and corticosteroid implants exist, predicting response remains a challenge. Hear Dr. MiTargeting Senescent Cells
https://reachmd.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseases